Abbott
ABT
$106.20
+1.56%
Abbott Laboratories is a diversified global healthcare enterprise operating four core segments — Medical Devices (rhythm management, electrophysiology, structural heart, diabetes care, neuromodulation), Diagnostics (lab systems, molecular and point-of-care testing), Nutritional Products (pediatric and adult nutrition), and Established Pharmaceuticals (branded generics largely sold in emerging markets) — with roughly 115,000 employees and a portfolio spanning consumables, capital equipment, and consumer health. Its competitive identity rests on scale and diversification: it is one of the few medtech players with leading positions across devices, diagnostics, and nutrition simultaneously, which smooths cyclicality but historically dampened the growth multiple relative to purer-play device peers. The current investor narrative is dominated by portfolio reshaping — management's decision to spin off the nutrition business to create a leaner, faster-growing medtech and diagnostics company, alongside the strategic acquisition of Exact Sciences to deepen its cancer diagnostics franchise — set against a 2026 guidance cut that overshadowed a solid Q1 earnings beat and has kept the stock in a recovery mode after a sharp drawdown. Debate centers on whether the simplified post-spin structure and diagnostics expansion can reaccelerate growth toward high-single digits, or whether tariff and reimbursement headwinds plus the dilutive optics of large M&A will keep the shares range-bound; the 54-year dividend increase streak and low-beta defensive profile continue to anchor the long-term income case.…
ABT
Abbott
$106.20
Related headlines
ABT 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Abbott's 12-month outlook, with a consensus price target around $118.52 and implied upside of +11.6% versus the current price.
Average Target
$118.52
0 analysts
Implied Upside
+11.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$100 - $130
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: ABT Investment Factors
The bull case currently has the stronger evidence: a unanimous strong_buy consensus with a $118.60 average target (14.4% upside), a forward PE of 17.4x versus 33.5x trailing, 13.0% revenue growth, 58% gross margins, $8.72B of free cash flow, and a 0.58 beta that makes the stock a natural defensive holding. The bear case rests on real but largely backward-looking damage — a 17.9% one-year decline, a guidance cut, and a 39.6% max drawdown — that has already reset expectations. The single most important tension is whether the post-spin, diagnostics-expanded Abbott can deliver the $7.94 consensus EPS that the 17.4x forward multiple is implicitly betting on; if that number holds, the stock is cheap, and if it slips again, the multiple has further to compress. Secondary tension: the market has already rewarded the six-month recovery (+13.8%) and the stock sits just 0.7% below the analyst low target, meaning near-term upside now depends on estimate revisions rather than multiple re-rating.
Bullish
- Analyst consensus firmly bullish: All 26 covering analysts rate ABT a 'strong_buy' with a mean recommendation of 1.46, and the average target price of $118.60 implies roughly 14.4% upside from the $103.70 close. Even the lowest target of $103.00 sits essentially at the current price, meaning the Street sees almost no downside from here on a fundamental basis.
- Forward earnings multiple is undemanding: At a forward PE of 17.4x against trailing PE of 33.5x, the market is pricing a sharp earnings recovery — consensus EPS of $7.94 versus trailing EPS of roughly $3.10. The PEG ratio of -0.65 reflects depressed trailing earnings rather than a broken growth story, and the forward multiple is well below the ~33x trailing level.
- Revenue reaccelerating with margin expansion: Q2 2026 revenue of $12.59B grew 13.0% year-over-year versus $11.14B in Q2 2025, and gross margin rose to 58.0% from 56.4% a year earlier. This is the strongest growth print in the dataset and suggests the medtech and diagnostics franchises are inflecting.
- Fortress balance sheet and cash generation: Debt-to-equity of just 0.29 and a current ratio of 1.58 leave ample financial flexibility, while trailing free cash flow of $8.72B comfortably funds the 1.88% dividend (payout ratio 63%) and the Exact Sciences acquisition. The 54-year dividend increase streak and 409 consecutive quarterly dividends underscore the durability of the cash engine.
Bearish
- Severe one-year underperformance: ABT is down 17.9% over 12 months and 16.5% year-to-date while SPY gained 13.1% and 11.5% respectively, producing relative strength of -31.0% over one year and -27.9% YTD. The stock remains 21.5% below its 52-week high of $132.03, and the max drawdown of -39.6% shows how violent the de-rating has been.
- 2026 guidance cut damaged credibility: The April 2026 annual profit guidance cut overshadowed a solid Q1 earnings beat and triggered the sharp drawdown from the $90s into the low $80s. Guidance resets of this kind typically compress the multiple until management re-establishes a track record of conservative, beatable targets.
- Earnings quality is volatile and optically poor: Trailing EPS of roughly $3.10 against a $103.70 price yields a 33.5x trailing PE, and quarterly EPS has swung from $1.02 (Q4 2025) to $0.53 (Q2 2026). Net margin of 14.7% and operating margin of 18.2% are below the company's own historical Q4 2025 levels of 15.5% and 19.6%, signaling near-term margin pressure.
- M&A and spin-off execution risk: The Exact Sciences acquisition deepens cancer diagnostics but carries dilutive optics and integration risk, while the nutrition spin-off adds structural complexity during a period of already-thin earnings visibility. Investors are being asked to underwrite two major corporate actions simultaneously while the core multiple is under pressure.
ABT Technical Analysis
Beta
0.58
0.58x market volatility
Max Drawdown
-38.7%
Largest decline past year
52-Week Range
$82-$132
Price range past year
Annual Return
-14.8%
Cumulative gain past year
| Period | ABT Return | S&P 500 |
|---|---|---|
| 1m | +7.5% | -0.9% |
| 3m | +0.5% | +1.2% |
| 6m | +18.7% | +4.9% |
| 1y | -14.8% | +11.2% |
| ytd | -14.5% | +10.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABT Fundamental Analysis
Quarterly Revenue
$12.6B
2026-06
Revenue YoY Growth
+13.0%
YoY Comparison
Gross Margin
58.0%
Latest Quarter
Free Cash Flow
$8.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABT Overvalued?
PE
33.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 21x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on earnings quality and margin trajectory. Trailing EPS of roughly $3.10 produces a 33.5x trailing PE that is only justified by the $7.94 consensus forward EPS, so any shortfall in that recovery path would leave the stock optically expensive. Operating margin fell to 18.2% TTM from 19.6% in Q4 2025, and quarterly EPS dropped from $1.02 to $0.53 sequentially, showing real volatility beneath the headline 13.0% revenue growth. The Exact Sciences acquisition adds integration and dilution risk, and the nutrition spin-off introduces structural complexity — two large corporate actions being executed while the core margin is under pressure. Debt is not the issue (D/E of 0.29, current ratio 1.58), but the 63% payout ratio leaves limited room for a margin shock without pressuring the 54-year dividend growth streak.
Market and competitive risks are dominated by valuation compression and sector rotation. At 4.94x sales, 4.25x EV/sales, and 18.9x EV/EBITDA, ABT trades at a premium that assumes successful portfolio reshaping; if the spin-off or Exact Sciences integration disappoints, the multiple has room to compress toward the medtech peer group. Beta of 0.583 is a double-edged sword — it cushions drawdowns but also means ABT lags in strong risk-on rallies, as evidenced by the -31.0% one-year relative strength versus SPY. The April 2026 guidance cut on tariff and reimbursement headwinds remains an unresolved overhang, and with rate-hike fears resurfacing, defensive healthcare is in favor today but could rotate out quickly if growth expectations reaccelerate elsewhere.
Worst-case scenario: the forward EPS recovery stalls (consensus $7.94 proves unreachable), the Exact Sciences deal dilutes earnings more than expected, and the nutrition spin-off is executed at a weak valuation, forcing another guidance reset. In that chain, the stock would retest its 52-week low of $81.97 — a decline of roughly 21% from the current $103.70 — and a break below that level would open the door toward the -39.6% max drawdown zone implied by the prior peak-to-trough move. Realistically, an investor could lose 20-25% from current levels in this adverse scenario, with the analyst low target of $103.00 offering essentially no downside protection since it sits at today's price.